ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.24
-0.71%
US Tech 100
20,072.80
-1.06%
S&P 500
5,789.93
-0.64%
US Dollar vs CAD
1.44043
-0.09%
Bitcoin
92,363.32
-2.24%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC

  6. Parnell Pharmaceuticals Holdings Ltd (CE) (PARNF) Share Price

Parnell Pharmaceuticals Holdings Ltd (CE)

Parnell Pharmaceuticals Holdings Ltd (CE) (PARNF)

USOTC
0.12
0.00
( 0.00% )
Updated: 18:00:00
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.12
Bid
0.00
Ask
0.00
Volume
-
0.00 Day's Range 0.00
0.000001 52 Week Range 0.35
Market Cap
14.445M
Previous Close
0.12
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
31,574
Shares Outstanding
120,377,529
Dividend Yield
-
PE Ratio
-2.52
Earnings Per Share (EPS)
-0.05
Revenue
35.43M
Net Profit
-5.74M

About Parnell Pharmaceuticals Holdings Ltd (CE)

Parnell (OTC: PARNF) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal and human health solutions. Parnell is a technology and clinical science leader in dairy reproduction, marketing its proprietary brands estroPLAN and GONAbreed... Parnell (OTC: PARNF) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal and human health solutions. Parnell is a technology and clinical science leader in dairy reproduction, marketing its proprietary brands estroPLAN and GONAbreed via its dedicated sales force and digital technology mySYNCH in the USA and Australia-New Zealand, and via distributors in other markets. Parnell has a rapidly growing contract manufacturing business supplying industry majors with specialized sterile injectable products. In companion animal, Parnell manufactures and markets its proprietary canine osteoarthritis brands Zydax and Glyde. For more information on the company and its products, please visit www.parnell.com. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.parnell.com
Headquarters
Sydney, New South Wales, Aus
Founded
-
Parnell Pharmaceuticals Holdings Ltd (CE) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker PARNF. The last closing price for Parnell Pharmaceuticals (CE) was US$0.12. Over the last year, Parnell Pharmaceuticals (CE) shares have traded in a share price range of US$ 0.000001 to US$ 0.35.

Parnell Pharmaceuticals (CE) currently has 120,377,529 shares outstanding. The market capitalization of Parnell Pharmaceuticals (CE) is US$14.45 million. Parnell Pharmaceuticals (CE) has a price to earnings ratio (PE ratio) of -2.52.

Ask ADVFN Intelligence (AI)

PARNF Latest News

More News

Parnell Pharmaceuticals Holdings Ltd Files Form 25, Voluntarily Delisting Its Shares From NASDAQ

OVERLAND PARK, Kan., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...

December 19 2016
GlobeNewswire Inc.

Parnell Pharmaceuticals Holdings Ltd Announces Intention To Move From the NASDAQ OMX Global Market and Expects To Move To the...

OVERLAND PARK, Kan., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...

December 09 2016
GlobeNewswire Inc.

Parnell Pharmaceuticals Holdings Ltd Announces $20 Million Secured Term Loan Facility

OVERLAND PARK, Kan., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...

November 22 2016
GlobeNewswire Inc.

Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Nine-Month Period Ended September 30, 2016

OVERLAND PARK, Kansas, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...

November 02 2016
GlobeNewswire Inc.

Parnell to Report Financial Results for the Nine Months Ended September 30, 2016 on November 2, 2016

OVERLAND PARK, Kan., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...

October 27 2016
GlobeNewswire Inc.

Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended June 30, 2016

OVERLAND PARK, Kan., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...

August 04 2016
GlobeNewswire Inc.

Parnell to Report Financial Results for the Six Months Ended June 30, 2016 on August 4, 2016

OVERLAND PARK, Kan., July 26, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...

July 26 2016
GlobeNewswire Inc.

Parnell Pharmaceuticals Holdings Ltd Announces Contract Manufacturing Agreement with Merial

OVERLAND PARK, Kan., May 31, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...

May 31 2016
GlobeNewswire Inc.

Parnell Pharmaceuticals Holdings Ltd Announces Pricing of an Underwritten Public Offering of Common Stock

OVERLAND PARK, Kan., May 12, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...

May 12 2016
GlobeNewswire Inc.

Parnell Pharmaceuticals Holdings Ltd Announces First Quarter Business Update

Parnell continues to grow rapidly with revenue increasing 43% for the three months ended March 31, 2016OVERLAND PARK, Kan., April 22, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings...

April 22 2016
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1000.120.120.12451950.12CS
40.071400.050.350.05239970.12424914CS
120.071400.050.350.05315740.08762036CS
260.11991199000.00010.351.0E-6222440.08610534CS
520.119999119999001.0E-60.351.0E-6156250.08387349CS
1560.1198599000.00020.351.0E-6133380.02869895CS
260-0.03-200.150.891.0E-6124380.2151003CS

PARNF - Frequently Asked Questions (FAQ)

What is the current Parnell Pharmaceuticals (CE) share price?
The current share price of Parnell Pharmaceuticals (CE) is US$ 0.12
How many Parnell Pharmaceuticals (CE) shares are in issue?
Parnell Pharmaceuticals (CE) has 120,377,529 shares in issue
What is the market cap of Parnell Pharmaceuticals (CE)?
The market capitalisation of Parnell Pharmaceuticals (CE) is USD 14.45M
What is the 1 year trading range for Parnell Pharmaceuticals (CE) share price?
Parnell Pharmaceuticals (CE) has traded in the range of US$ 0.000001 to US$ 0.35 during the past year
What is the PE ratio of Parnell Pharmaceuticals (CE)?
The price to earnings ratio of Parnell Pharmaceuticals (CE) is -2.52
What is the cash to sales ratio of Parnell Pharmaceuticals (CE)?
The cash to sales ratio of Parnell Pharmaceuticals (CE) is 0.41
What is the reporting currency for Parnell Pharmaceuticals (CE)?
Parnell Pharmaceuticals (CE) reports financial results in AUD
What is the latest annual turnover for Parnell Pharmaceuticals (CE)?
The latest annual turnover of Parnell Pharmaceuticals (CE) is AUD 35.43M
What is the latest annual profit for Parnell Pharmaceuticals (CE)?
The latest annual profit of Parnell Pharmaceuticals (CE) is AUD -5.74M
What is the registered address of Parnell Pharmaceuticals (CE)?
The registered address for Parnell Pharmaceuticals (CE) is UNIT 4 CENTURY ESTATE, 476 GARDENERS ROAD, ALEXANDRIA, SYDNEY, NEW SOUTH WALES, 2015
What is the Parnell Pharmaceuticals (CE) website address?
The website address for Parnell Pharmaceuticals (CE) is www.parnell.com
Which industry sector does Parnell Pharmaceuticals (CE) operate in?
Parnell Pharmaceuticals (CE) operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VICPVicapsys Life Sciences Inc (CE)
US$ 1.50
(149,999,900.00%)
200
INTKIndustrial Nanotech Inc (PK)
US$ 0.0001
(9,900.00%)
500k
BORKBourque Industries Inc (CE)
US$ 0.0001
(9,900.00%)
579.7k
PSRUValiant Eagle Inc (PK)
US$ 0.0001
(9,900.00%)
200k
MOPNMOP Environmental Solutions Inc (CE)
US$ 0.0001
(9,900.00%)
32k
IFANIFAN Financial Inc (CE)
US$ 0.000001
(-99.50%)
1,000
VGTLVGTel Inc (CE)
US$ 0.000001
(-99.50%)
200k
UBQUUbiquitech Software Corp (PK)
US$ 0.000001
(-99.00%)
1.73M
GLCOGlobal Links Corporation New (CE)
US$ 0.000001
(-99.00%)
1.5k
TMPOQTempo Automation Holdings Inc (CE)
US$ 0.0001
(-97.96%)
100
ABQQAB International Group Corporation (PK)
US$ 0.0007
(0.00%)
124.38M
TGGITrans Global Group Inc (CE)
US$ 0.0002
(100.00%)
62.27M
SIRCSolar Integrated Roofing Corporation (PK)
US$ 0.0001
(0.00%)
38.8M
HMBLHUMBL Inc (PK)
US$ 0.00085
(-5.56%)
33.71M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.00365
(-2.67%)
29.3M

Discussion

View Full Feed
BottomBounce BottomBounce 2 minutes ago
Why NIO Inc. (NIO) Is One of the Best Penny Stocks to Invest In According to Media? https://finance.yahoo.com/news/why-nio-inc-nio-one-142643929.html
NIO
north40000 north40000 2 minutes ago
JNJ buys ITCI for ~ 4.8 Billion.
JNJ
gawti88 gawti88 2 minutes ago
No need to hope. Just wait. It's go time soon. Fins almost done, things will flip fast.
CEOS
Donotunderstand Donotunderstand 2 minutes ago
Warren and Bessent will agree on near zero

Bessent is qualified
FNMA
firebag1 firebag1 2 minutes ago
lets hope so!! im not going anywhere
HMBL
Invest-in-America Invest-in-America 3 minutes ago
TRAW: As I noted, pure JUNK!!!! (Or, the MOUSE that roared, for a minute!!!)
TRAW
RMS555 RMS555 3 minutes ago
🖕Jonathan Bishop and Your Pumpers!!
NNRX
europa7 europa7 3 minutes ago
SEALSQ in Cooperation with WISeKey Expands Post-Quantum Footprint in Saudi Arabia
Riyadh, Saudi Arabia, Jan. 13, 2025
https://www.stocktitan.net/news/LAES/sealsq-in-cooperation-with-wi-se-key-expands-post-quantum-footprint-8t64vsnpc29b.html

-- Partnership with Saudi Mini
LAES
BottomBounce BottomBounce 3 minutes ago
Why NIO Inc. (NIO) Is One of the Best Penny Stocks to Invest In According to Media? https://finance.yahoo.com/news/why-nio-inc-nio-one-142643929.html
NIO
Donotunderstand Donotunderstand 4 minutes ago
I do not remember being the one to ask

I am certain the Executive branch in this case does not have to listen to CBO at all - in areas like killing the LP/SP IOU ---- or exercising the warrants ---- Treasury can do both regardless off CBO

other stuff - the involves
FNMA
OPKOHEALTH2022 OPKOHEALTH2022 4 minutes ago
You can listen to hoghead or you can listen to a professional analysts. Would you listen to your doctor or someone that tells you otherwise about your health ? Just keeping things real here now. That’s all folks .
FCEL
RMS555 RMS555 4 minutes ago
Some questions for the "top traders" of PSRU:
Who is Ezzat El Jallad and how can he receive billions of shares for "debt conversion" when there are no monies owed to him? His name shows up here (page 7& 8): https://www.otcmarkets.com/otcapi/company/financial-report/416039/content What happen
PSRU
RickNagra RickNagra 4 minutes ago
style="caret-color: rgb(35, 42, 49); color: rgba(35, 42, 49, 1); font-family: "GT America", "Yahoo Sans", YahooSans, "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 15.75px; background-color: rgba(255, 255, 255, 1)"Warren’s letter also covers a wide array of Bessent’s other coming respons
FNMA
Stevenvegas Stevenvegas 5 minutes ago
in 1.99 for day/swing
HOLO
AlwaysKing AlwaysKing 5 minutes ago
$UMAV ~I'm seeing this running beyond $1.50 per share and possibly $5+ per share on just the $1.5 billion in incoming contracts with our tiny share structure we have as seen here:
UMAV SECURITY DETAILS
Share Structure:
Market Cap Market Cap:
3,356,242
01/10/202
UMAV
2cents4one 2cents4one 5 minutes ago
Yes Benyam,
I have encouraged friends to join in on this adventure. This one really could be a "dream come true" kind of stock. Hoping and praying
UMAV
Gizzer211 Gizzer211 5 minutes ago
HOLO 2.06
HOLO
jcromeenes jcromeenes 5 minutes ago
Not a strong first hour. I think we end up taking our lumps today. All good, Thursday is coming.
FNMA
I am done I am done 5 minutes ago
$CBDW 1606 Corp. Applauds Adnexus Biotechnologies' Launch of Trapicolast:
https://www.accesswire.com/967412/1606-corp-applauds-adnexus-biotechnologies-launch-of-trapicolast-a-revolutionary-new-ai-driven-malaria-drug
CBDW
al44 al44 5 minutes ago
Climate Jeezus Taketh Away

"State Farm, my insurer for decades, canceled my insurance and everyone in our immediate neighborhood just before the fire. State Farm WASN’T there. . . ." — James Woods

James Howard Kunstler
Jan 13, 2025

“So-called progr
GetSeriousOK GetSeriousOK 5 minutes ago
Here's why your forecast is pure P&D nonsense. $1.5 million annual revenue (or a $400k quarter) = break even, cash flow positive: PPS = .01. Didn't happen in 2021 so why would it happen now? In January 2021 they disclosed that Q4 2020 revenue was over $500k. All of OTC pink biotech was being manipu
BIEL
gp22 gp22 5 minutes ago
$MITQ @ 70s: In more...Volume elevating....Last of the AI microfloats
MITQ
georgebailey georgebailey 5 minutes ago
Steady yes I’d say optimistic as well. But, if the RWE is well controlled and stat sig then it’s no longer optimistic and L would command a broad scope.
I expect no less than grade 3 and 4 approval based on the pediatric trial approval.
NWBO

Your Recent History

USOTC
PARNF
Parnell Pharmaceuticals (CE)
BIT
F22667
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads